Organization
University of Pittsburgh School of Medicine
17 abstracts
Abstract
Long-term follow up of E3311, a phase II trial of transoral surgery (TOS) followed by pathology-based adjuvant treatment in HPV-associated (HPV+) oropharynx cancer (OPC): A trial of the ECOG-ACRIN Cancer Research Group.Org: Yale University School of Medicine and Yale Cancer Center, Dana Farber Cancer Institute – ECOG-ACRIN Biostatistics Center, Johns Hopkins University, University of Pennsylvania Medical Center, University of Maryland Marlene and Stewart Greenebaum Cancer Center,
Abstract
A phase III trial evaluating addition of adjuvant chemotherapy to ovarian function suppression + endocrine therapy in premenopausal women with pN0-1, HR+/HER2- breast cancer (BC) and oncotype recurrence score (RS) ≤25 (OFSET): NRG-BR009.Org: Georgetown Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, MedStar Health, University of Pittsburgh School of Public Health, University of Pittsburgh Medical Center (UPMC),
Abstract
A phase III randomized trial of radiotherapy optimization for low-risk HER2-positive breast cancer (HERO): NRG-BR008.Org: Memorial Sloan Kettering Cancer Center, The University of Texas MD Anderson Cancer Center, NRG Oncology Statistical and Data Management Center, Department of Biostatistics at University of Pittsburgh School of Public Health, Women and Infants Hospital of Rhode Island,
Abstract
NRG-BR007: A phase III trial evaluating de-escalation of breast radiation (DEBRA) following breast-conserving surgery of stage 1, HR+, HER2-, RS ≤18 breast cancer.Org: University of Kansas Medical Center Comprehensive Cancer Center (KUMC CCC), Department of Biostatistics, University of Pittsburgh School of Public Health, St. Luke’s University Health Network Cancer Center, Orlando Health Cancer Institute, The Ohio State University Comprehensive Cancer Center,
Abstract
Adoption of the International Cognition and Cancer Task Force recommendations for harmonizing studies of cancer-related cognitive impairment: A systematic review of published literature.Org: University of Pittsburgh School of Medicine, UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, PA,
Abstract
Association between socioeconomic factors and utilization of next-generation sequencing in metastatic breast cancer.Org: University of Pittsburgh School of Medicine, University of Pittsburgh Medical Center (UPMC), University of Pittsburgh, Pittsburgh, PA,
Abstract
Colon adjuvant chemotherapy based on evaluation of residual disease (CIRCULATE-NORTH AMERICA): NRG-GI008.Org: The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, NRG Oncology Statistical and Data Management Center, Department of Biostatistics at University of Pittsburgh School of Public Health, UPMC Hillman Cancer Center, NSABP Foundation, Inc. Pathology Lab,
Abstract
Phase II trial of adjuvant de-escalated radiation + adjuvant nivolumab for intermediate-high risk P16+ oropharynx cancer.Org: UPMC Hillman Cancer Center, Department of Radiation Oncology, Sichuan Cancer Hospital & Institute, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China, Helen F. Graham Cancer Center and Research Institute, Newark, DE, University of Pittsburgh Department of Otolaryngology, University of Pittsburgh Medical Center,
Abstract
Tarlatamab in small cell lung cancer (SCLC): Safety and efficacy analyzed by baseline brain metastasis.Org: Gustave Roussy Département d'Organisation du Parcours Patient, Chris O'Brien Lifehouse, Washington University Medical School, Hospital Universitario 12 de Octubre, University of Pittsburgh School of Medicine,
Abstract
Phase II/III study of circulating tumor DNA as a predictive biomarker in adjuvant chemotherapy in patients with stage II colon cancer: NRG-GI005 (COBRA).Org: University of Texas MD Anderson Cancer Center, University of Pittsburgh, Pittsburgh, PA, NRG Oncology SDMC, UPMC Hillman Cancer Center, NSABP Foundation,
Abstract
Neoadjuvant nivolumab alone or in combination with relatlimab or ipilimumab in resectable head and neck squamous cell carcinoma (HNSCC).Org: University of Pittsburgh Cancer Institute, University of Pittsburgh, Pittsburgh, PA, University of Pittsburgh Medical Center, University of Pittsburgh School of Medicine, University of Pittsburgh Department of Otolaryngology,
Abstract
Differences in real-world pembrolizumab dosing patterns (every 3 weeks versus every 6 weeks) across a large cancer center network.Org: University of Pittsburgh School of Medicine, Department of Medicine, Icahn School of Medicine at Mount Sinai, Division of Hematology/Oncology, Department of Medicine, University Of Toledo, Department of Biostatistics, Yamaguchi University Graduate School of Medicine, Yamaguchi, Japan, UPMC Hillman Cancer Center Biostatistics Facility,
Abstract
Outcomes by time to adjuvant therapy in E3311, a phase II trial of transoral surgery (TOS) followed by pathology-based adjuvant treatment in HPV-associated (HPV+) oropharynx cancer (OPC): A trial of the ECOG-ACRIN Cancer Research Group.Org: Hillman Cancer Center, Pittsburgh, PA, Pittsburgh, PA, Dana Farber Cancer Institute – ECOG-ACRIN Biostatistics Center, Boston, MA, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins,
Abstract
Prognostic significance of immune-related adverse events and immunosuppression in patients with melanoma receiving adjuvant anti-PD-1 therapy.Org: University of Pittsburgh Medical Center, H. Lee Moffitt Cancer Center and Research Institute, University of Pittsburgh School of Medicine, Jordan University of Science and Technology, University of Pittsburgh Graduate School of Public Health,
Abstract
Can axillary lymph node dissection (ALND) be omitted in patients with breast cancer with persistent axillary disease after neoadjuvant chemotherapy?Org: University of Pittsburgh, Pittsburgh, PA, University of Pittsburgh School of Medicine,
Abstract
Recurrence free survival in patients with HPV+ head and neck cancer treated with TORS and neck dissection.Org: University of Pittsburgh Medical Center, University of Pittsburgh School of Medicine, University of Pittsburgh Department of Otolaryngology, University of Pittsburgh, Pittsburgh, PA,
Abstract
Association of patient and tumor characteristics with outcomes in young patients with head and neck squamous cell carcinoma (HNSCC).Org: University of Pittsbugh Medical Center, University of Pittsburgh Cancer Institute, University of Pittsburgh, Pittsburgh, PA, University of Pittsburgh Department of Otolaryngology, University of Pittsburgh Medical Center Cancer Center,